Insights

C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.

Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.

At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.

At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.

Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.

Andrew Evens, DO, MBA, MSc shared the latest updates and therapeutic advancements for the treatment of follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.

Joanna Rhodes, MD, MSCE discusses advances in frontline treatment, including bispecific antibodies and T-cell therapies, for patients with follicular lymphoma at the 20205 Lymphoma, Leukemia & Myeloma Winter Symposium.

Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.

John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.

Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.